Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 1/2011

Open Access 01-12-2011 | Review

Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research

Authors: Delphine Sculier, Haileyesus Getahun, Christian Lienhardt

Published in: Journal of the International AIDS Society | Special Issue 1/2011

Login to get access

Abstract

Operational research is necessary to improve the access to and delivery of tuberculosis prevention, diagnosis and treatment interventions for people living with HIV. We conducted an extensive review of the literature and reports from recent expert consultations and research-related meetings organized by the World Health Organization and the Stop TB Partnership to identify a TB/HIV operational research agenda. We present critical operational research questions in a series of key areas: optimizing TB prevention by enhancing the uptake of isoniazid preventive therapy and the implementation of infection control measures; assessing the effectiveness of existing diagnostic tools and scaling up new technologies; improving service delivery models; and reducing risk factors for mortality among TB patients living with HIV. We discuss the potential impact that addressing the operational research questions may have on improving programmes’ performance, assessing new strategies or interventions for TB control, or informing global or national policy formulation. Financial resources to implement these operational research questions should be mobilized from existing and new funding mechanisms. National TB and HIV/AIDS programmes should develop their operational research agendas based on these questions, and conduct the research that they consider crucial for improving TB and HIV control in their settings in collaboration with research stakeholders.
Literature
1.
Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P: Tuberculosis and HIV: current status in Africa. AIDS. 1997, 11 (Suppl B): S115-123.PubMed
2.
Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC: Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010, 375 (9728): 1814-1829. 10.1016/S0140-6736(10)60483-7.CrossRefPubMed
3.
WHO: Global tuberculosis control: 2010 Report. 2010, Geneva, Switzerland: World Health Organization
4.
Stop TB Partnership, WHO: The Global Plan to Stop TB 2011-2015. Transforming the fight towards elimination of Tuberculosis. 2010, Geneva, Switzerland: Stop TB Partnership
5.
WHO: Operational research for malaria control: tutor’s guide. 2003, Geneva, Switzerland: World Health Organization
6.
Harries AD: Integration of operational research into National Tuberculosis Control Programmes. Tuberculosis. 2003, 83 (1-3): 143-147. 10.1016/S1472-9792(02)00061-6.CrossRefPubMed
7.
Laserson KF, Binkin NJ, Thorpe LE, Laing R, Iademarco MF, Bloom A, Agerton TB, Nelson L, Cegielski JP, Ferroussier O, Holtz T, Vitek E, Gammino V, Tan K, Finlay A, Dewan P, Miranda A, Aquino G, Weyer K, Sy DN, Vernon A, Becerra J, Ershova J, Wells CD: Capacity building for international tuberculosis control through operations research training. Int J Tuberc Lung Dis. 2005, 9 (2): 145-150.PubMed
8.
Zachariah R, Harries AD, Ishikawa N, Rieder HL, Bissell K, Laserson K, Massaquoi M, Van Herp M, Reid T: Operational research in low-income countries: what, why, and how?. Lancet Infect Dis. 2009, 9 (11): 711-717. 10.1016/S1473-3099(09)70229-4.CrossRefPubMed
9.
Lienhardt C, Cobelens F: Operational research for improved TB control: the scope, the needs and the way forward. Int J Tuberc Lung Dis. 2011, 15 (1): 6-13.PubMed
10.
Smart T: Catalysing HIV/TB research: a meeting report. HIV & AIDS Treatment in Practice. 2009, London, UK: NAM
11.
12.
13.
14.
15.
WHO: Promotion and Rationalization of Operational Research Activities in TB Control. Draft Workshop Report. 2010, Geneva, Switzerland: World Health Organization
16.
WHO: Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings. 2010, Geneva, Switzerland: World Health Organization
17.
WHO: Interim Policy on Collaborative TB/HIV Activities. 2004, Geneva, Switzerland: World Health Organization, 1
18.
Chamie G, Luetkemeyer A, Charlebois E, Havlir DV: Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 2010, 50 (Suppl 3): S245-254.PubMedCentralCrossRefPubMed
19.
Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010, CD000171-1
20.
Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione MC: Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010, 24 (Suppl 5): S57-65. 10.1097/01.aids.0000391023.03037.1f.CrossRefPubMed
21.
Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD: Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010, 24 (Suppl 5): S45-48. 10.1097/01.aids.0000391021.18284.12.CrossRefPubMed
22.
WHO: Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. 2010, Geneva, Switzerland: World Health Organization
23.
Getahun H, Kittikraisak W, Heilig CM, Corbett E, Ayles H, Cain KP, Grant AD, Churchyard G, Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date A, Varma JK: Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. PLoS Med. 2011, 8 (1):
24.
WHO: Report of a "Lessons Learnt" Workshop on the six ProTEST Pilot Projects in Malawi, South Africa and Zambia. 2004, Geneva: World Health Organization
25.
Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE: Isoniazid preventive therapy for HIV-infected people: evidence to support implementation. AIDS. 2010, 24 (Suppl 5): S1-3. 10.1097/01.aids.0000391009.95149.ec.CrossRefPubMed
26.
Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ: Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS. 2010, 24 (Suppl 5): S29-36. 10.1097/01.aids.0000391019.10661.66.CrossRefPubMed
27.
Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda N, Mosimaneotsile B, Motsamai O, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx PH, Castro KG, Wells CD: 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011
28.
Martinson N, Barnes G, Msandiwa R, Gray G, Mclntyre J, Hausler H, Ram M, Chaisson RE: Novel Regimens for Treating Latent TB in HIV-infected Adults in South Africa: A Randomized Clinical Trial. 16th Conference on Retroviruses and Opportunistic Infections. 2009, Montreal, Canada
29.
Swaminathan S, Menon P, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiah P, lliayas S, Chandrasekaran P, Narayanan P: Efficacy of a 6-month vs a 36-month Regimen for Prevention of TB in HIV-infected Persons in India: A Randomized Clinical Trial. 17th Conference on Retroviruses and Opporunistic Infections. 2010, San Francisco, USA
30.
Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ: Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet. 2010, 10: 489-498. 10.1016/S1473-3099(10)70078-5.CrossRefPubMed
31.
WHO: WHO Policy on TB Infection Control in Health -Care Facilities, Congregate Settings and Households. 2009, Geneva: World Health Organization
32.
Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK: Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009, 15 (2): 258-264. 10.3201/eid1502.080942.PubMedCentralCrossRefPubMed
33.
WHO: Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. 2007, Geneva, Switzerland: World Health Organization
34.
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, AIland D, Perkins MD: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010, 363 (11): 1005-15. 10.1056/NEJMoa0907847.PubMedCentralCrossRefPubMed
35.
WHO: Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-76. 2010, Geneva, Switzerland: World Health Organization
36.
37.
Lawn SD, Kranzer K, Wood R: Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009, 30 (4): 685-699. 10.1016/j.ccm.2009.08.010. viiiPubMedCentralCrossRefPubMed
38.
O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR: Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009, 13 (7): 855-861.PubMedCentralPubMed
39.
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C: Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010, 375 (9728): 1798-1807. 10.1016/S0140-6736(10)60492-8.CrossRefPubMed
40.
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, EI-Sadr W, Friedland G, Abdool Karim Q: Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010, 362 (8): 697-706. 10.1056/NEJMoa0905848.PubMedCentralCrossRefPubMed
41.
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y: Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroivral treatment (HAART) in severelyÌmmunosuppressed HIV-infected adults with newly diagnosed tuberculosis. XVIII International AIDS Conference. 2010, Vienna, Austria
42.
Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, Kumwenda J, Qasba S, Hogg E, Anderson J, Sanne I, A5521team: International Randomized Trial of Immediate vs. Early ART in HIV+ Patients treated for TB: ACTG 5221 STRIDE study. 18th Conference on Retroviruses and Opportunistic Infections. 2011, Boston, USA
43.
Abdool Karim SS, Naidoo K, Padayatchi N, Grobler A, Baxter C, El-Sadr W, Friedland G, Abdool Karim Q: Optimal timing of ART during TB Therapy. Findings of the SAPIT Trial. 18th Conference on Retroviruses and Opportunistic Infections. 2011, Boston, USA
44.
WHO: An tiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. 2010, Geneva, Switzerland: World Health Organization
45.
Pope DS, Deluca AN, Kali P, Hausler H, Sheard C, Hoosain E, Chaudhary MA, Celentano DD, Chaisson RE: A cluster-randomized trial of provider-initiated (opt-out) HIV counseling and testing of tuberculosis patients in South Africa. J Acquir Immune Defic Syndr. 2008, 48 (2): 190-195. 10.1097/QAI.0b013e3181775926.PubMedCentralCrossRefPubMed
46.
Van Rie A, Sabue M, Jarrett N, Westreich D, Behets F, Kokolomani J, Bahati ER: Counseling and testing TB patients for HIV: evaluation of three implementation models in Kinshasa, Congo. Int J Tuberc Lung Dis. 2008, 12 (3 Suppl 1): 73-78.PubMed
47.
Porskorg A, Bjerregaard-Andersen M, Oliveira I, Joaquim LC, Camara C, Andersen PL, Rabna P, Aaby P, Wejse C: Enhanced tuberculosis identification through 1-month follow-up of smear negative tuberculosis suspects. Int J Tuberc Lung Dis. 2011, 15 (4): 459-464. 10.5588/ijtld.10.0353.CrossRef
48.
Suggaravetsiri P, Yanai H, Chongsuvivatwong V, Naimpasan O, Akarasewi P: Integrated counseling and screening for tuberculosis and HIV among household contacts of tuberculosis patients in an endemic area of HIV infection: Chiang Rai, Thailand. Int J TubercLung Dis. 2003, 7 (12 Suppl 3): S424-431.
49.
Lugada E, Levin J, Abang B, Mermin J, Mugalanzi E, Namara G, Gupta S, Grosskurth H, Jaffar S, Coutinho A, Bunnell R: Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr. 2010, 55 (2): 245-252. 10.1097/QAI.0b013e3181e9e069.CrossRefPubMed
50.
Legido-Quigley H, Montgomery CM, Khan P, Fakoya A, Getahun H, Grant AD: Integrating tuberculosis and HIV services in low and middle-income countries: a systematic review. Global symposium on health systems research. 2010, Montreux, Switzerland
51.
Getahun H, Raviglione M: Active case-finding for TB in the community: time to act. Lancet. 2010, 376 (9748): 1205-1206. 10.1016/S0140-6736(10)61503-6.CrossRefPubMed
52.
Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, Churchyard GJ, Williams BG, Munyati SS, Butterworth AE, Mason PR, Mungofa S, Hayes RJ: Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010, 376 (9748): 1244-1253. 10.1016/S0140-6736(10)61425-0.PubMedCentralCrossRefPubMed
53.
Datiko DG, Lindtjorn B: Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS ONE. 2009, 4 (5): e5443-10.1371/journal.pone.0005443.PubMedCentralCrossRefPubMed
54.
Kort R: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice -operations research. J Int AIDS Soc. 2010, 13 (Suppl 1): S5-10.1186/1758-2652-13-S1-S5.PubMedCentralCrossRefPubMed
55.
Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A: Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ. 2008, 337: a257-10.1136/bmj.a257.PubMedCentralCrossRefPubMed
56.
Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Gie RP, Cotton MF, van Helden PD, Warren RM, Beyers N: Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006, 42 (4): 548-558. 10.1086/499953.CrossRefPubMed
57.
Mansoor N, Scriba TJ, de Kock M, Tameris M, Abel B, Keyser A, Little F, Soares A, Gelderbloem S, Mlenjeni S, Denation L, Hawkridge A, Boom WH, Kaplan G, Hussey GD, Hanekom WA: HIV-1 infection in infants severely impairs the immune response induced by Baccile Calmette-Guerin vaccine. J Infect Dis. 2009, 199 (7): 982-990. 10.1086/597304.PubMedCentralCrossRefPubMed
58.
Gray DM, Zar H, Cotton M: Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev. 2009, CD006418-1
59.
WHO: Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006, Geneva, Switzerland: World Health Organization
60.
Marais BJ, Graham SM, Cotton MF, Beyers N: Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis. 2007, 196 (suppl 1): S76-85.CrossRefPubMed
61.
Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi A, Khandekar M, Karmarkar A, Kulkami V, Sastry J, Mave V, Suryavanshi N, Thakar M, Kulkarni S, Tripathy S, Sambarey P, Patil S, Paranjape R, Bollinger RC, Jamkar A, Six Week Extended-Dose Nevirapine Indiat Study Team: Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011, 203 (3): 358-363. 10.1093/jinfdis/jiq064.PubMedCentralCrossRefPubMed
62.
Chileshe M, Bond VA: Barriers and outcomes: TB patients co-infected with HIV accessing antiretroviral therapy in rural Zambia. AIDS Care. 2010, 22 (Supp11): 51-59.CrossRefPubMed
63.
Harrington M: Community involvement in HIV and tuberculosis research. J Acquir Immune Defic Syndr. 2009, 52 (Suppl 1): S63-66.CrossRefPubMed
64.
Chakaya J, Uplekar M, Mansoer J, Kutwa A, Karanja G, Ombeka V, Muthama D, Kimuu P, Odhiambo J, Njiru H, Kibuga D, Sitieni J: Public-private mix for control of tuberculosis and TB-HIV in Nairobi, Kenya: outcomes, opportunities and obstacles. Int J Tuberc Lung Dis. 2008, 12 (11): 1274-PubMed
65.
Harries AD, Rusen ID, Reid T, Detjen AK, Berger SD, Bissell K, Hinderaker SG, Edginton M, Fussell M, Fujiwara Pl, Zachariah R: The Union and Médecins Sans Frontiéres approach to operational research. Int J Tuberc Lung Dis. 2011, 15 (2): 144-154.PubMed
66.
Raviglione MC, Uplekar MW: WHO's new Stop TB Strategy. The Lancet. 2006, 367: 952-955. 10.1016/S0140-6736(06)68392-X.CrossRef
67.
Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, El-Sadr W, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A: Scale-up of services and research priorities for diagnosis, management and control of tuberculosis: a call to action. The Lancet. 2010, 375 (9732): 2179-2191. 10.1016/S0140-6736(10)60554-5.CrossRef
68.
Stop TB Policy Paper: contributing to health system strengthening: guiding principles for national tuberculosis control programmes. 2008, Geneva, World HeaIth Organization, WHO/HTM/TB/2008 400 2008
69.
Atun R, de JT, Secci F, Ohiri K, Adeyi O: A systematic review of the evidence on integration of targeted health interventions into health systems. Health Policy Plan. 2010, 25 (1): 1-14. 10.1093/heapol/czp053.CrossRefPubMed
Metadata
Title
Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research
Authors
Delphine Sculier
Haileyesus Getahun
Christian Lienhardt
Publication date
01-12-2011
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-14-S1-S5

Other articles of this Special Issue 1/2011

Journal of the International AIDS Society 1/2011 Go to the issue

Research

Adult mortality in the cities of Bulawayo and Harare, Zimbabwe: 1979-2008

Commentary

Treatment as prevention: preparing the way

Review

Antiretroviral drug supply challenges in the era of scaling up ART in Malawi

Editorial

Facing up to programmatic challenges created by the HIV/AIDS epidemic in sub-Saharan Africa

Research

Positive spill-over effects of ART scale up on wider health systems development: evidence from Ethiopia and Malawi

Debate

The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits